At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?
Shares:
Programming Note: Cost Curve is off tomorrow. Back Monday. Of course, that’s what I said last week, too, and look where that got me. There is a new analysis from
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv